Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach
ConclusionsThe long-term overall survival of the patients treated on S0816 remains high (94%) at 5 years. Despite historical data suggesting favorable clinical outcomes in patients with a negative PET2, nearly 25% of these patients experienced relapse events, demonstrating limitations of a PET-adapted approach and of standard frontline therapy with ABVD. In patients who were PET2+, PFS was favorable relative to historical series, but was associated with a high rate of secondary malignancies. Our results emphasize the importance of long-term follow-up in this disease, and the need for better biomarkers at diagnosis of HL and less toxic approaches for patients with a positive PET2.AcknowledgementIn memory of Oliver W. Press, principal investigator of this trial, who died in 2017.DisclosuresStraus: DAVA Oncology: Consultancy, Honoraria; Medical Crossfire: Speakers Bureau; Millenium (Takeda): Consultancy, Research Funding; JUNO: Consultancy; Bayer: Consultancy; Onco Tracker: Consultancy; Seattle Genetics: Consultancy; Roch China: Speakers Bureau; InPractice Elselvier: Consultancy; Memorial Sloan Kettering Cancer Center: Employment. Rimsza: NanoString: Other: Inventor on the patent for the Lymph2Cx assay. Bartlett: ImaginAB: Research Funding; Genentech: Research Funding; Forty Seven: Research Funding; Bristol-Meyers Squibb: Research Funding; Merck & Co: Research Funding; Novartis: Research Funding; Celgene: Research Funding; Gilead: Consultancy, Membership on an entity's Board...
Source: Blood - Category: Hematology Authors: Stephens, D. M., Li, H., Schoder, H., Straus, D. J., Moskowitz, C. H., Leblanc, M. L., Rimsza, L. M., Bartlett, N. L., Evens, A. M., LaCasce, A. S., Barr, P., Knopp, M. V., Hsi, E. D., Leonard, J. P., Kahl, B. S., Smith, S. M., Friedberg, J. W. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches Source Type: research
More News: AstraZeneca | Basal Cell Carcinoma | Bladder Cancer | Brain | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Cervical Cancer | Chemotherapy | China Health | Employment | Genetics | Heart | Heart Failure | History of Medicine | Hodgkin's Disease | Lymphoma | Melanoma | Merck | Myelodysplastic Syndrome | Nanotechnology | Neurology | Non-Hodgkin's Lymphoma | Peripheral Neuropathy | PET Scan | Pfizer | Pharmaceuticals | Prednisone | Skin Cancer | Squamous Cell Carcinoma | Study | Thyroid | Thyroid Cancer | Toxicology | Urology & Nephrology